All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 15, 2021
Home
» FDA approves Xpovio for multiple myeloma after at least one prior therapy
FDA approves Xpovio for multiple myeloma after at least one prior therapy
Dec. 21, 2020
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=175556
BioWorld Science
Related Articles
FDA approves Abecma for relapsed or refractory multiple myeloma
